Skip to main content
Fig. 1 | BMC Endocrine Disorders

Fig. 1

From: Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

Fig. 1

Patient disposition. Flowchart showing the number of patients who were randomized, completed the 12-month core study, entered the extension on their randomized treatment, and entered the extension after switching to the opposite treatment. Thirty-four patients entered the extension phase prior to implementation of the protocol amendment and received unblinded treatment during the extension; of these: *15 patients continued to receive their randomized treatment with pasireotide LAR and †19 crossed over from octreotide LAR to pasireotide LAR during the extension

Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us